Lakefront Biotherapeutics sets up second €50m stock repurchase, again through Morgan Stanley
The Euronext- and NASDAQ-listed company will buy back up to 4,604,550 of its own shares by 31 March 2027, a month after finishing its first €50m programme.
16 Nov 2026 · Lakefront Biotherapeutics · Company news
Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) said on 16 November 2026 that it will repurchase up to €50m of its own stock, capped at 4,604,550 shares. The window stays open until 31 March 2027 at the latest, so purchases could continue for about four and a half months.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Approvals & launchesAll →
Approvals & launches
FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
16 Nov 2026 · Roche · Company news
Approvals & launches
FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer
16 Nov 2026 · F. Hoffmann-La Roche Ltd · Company news
Approvals & launches
Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval
16 Nov 2026 · Larimar Therapeutics, Inc. LRMR · Company news
Approvals & launches
FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children
16 Nov 2026 · Essential Pharma · Company news
Approvals & launches
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
13 Nov 2026 · Imricor Medical Systems, Inc. · Company news
Approvals & launches
FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100
13 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news